Q4 2024 Earnings Call Transcript April 1, 2025 Operator: Hello and welcome to the AIM ImmunoTech Fourth Quarter and Full Year ...

Brian McNamara has a shot at beating his aggressive cancer, but his Aetna subsidiary insurance company doesn't want to pay ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...

The FDA approves AZN's sBLA seeking the expanded use of Imfinzi for adult patients with muscle-invasive bladder cancer.

Learn more about whether AstraZeneca PLC or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether AstraZeneca PLC or Corcept Therapeutics Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab) perioperative regimen has been approved by the US Food and Drug ...

EMA committee recommends approval of AstraZeneca’s Calquence plus chemoimmunotherapy to treat adult patients with mantle cell lymphoma: Cambridge, UK Tuesday, April 1, 2025, 17: ...

AstraZeneca shares have enjoyed moderate gains this year, helping to recover some of last year’s losses. But does it remain a ...

Imfinzi was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings.